A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2018
At a glance
- Drugs Cabozantinib (Primary) ; Crizotinib (Primary) ; Savolitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms PAPMET
- 28 Dec 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 31 Jul 2017 According to a Chi Med media release. Phase II efficacy results were presented at Genitourinary Cancers Symposium ASCO 2017.
- 31 Jul 2017 Results published in a Chi Med media release